Yu M L, Chuang W L, Dai C Y, Chen S C, Lin Z Y, Hsieh M Y, Tsai J F, Wang L Y, Chang W Y
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University, No. 100, Shih-Chuan 1st Road, Kaohsiung 807, Taiwan, ROC.
Antiviral Res. 2001 Dec;52(3):241-9. doi: 10.1016/s0166-3542(01)00165-6.
GB virus C/hepatitis G virus (GBV-C/HGV) RNA, detected by polymerase chain reaction, and antibodies to the GBV-C/HGV envelope protein (anti-E2), detected by an enzyme-linked immunosorbent assay, were used to evaluate both the impact of GBV-C/HGV on the coexistent hepatitis C virus (HCV) infection and the course of GBV-C/HGV infection in chronic hepatitis C patients with and without interferon-alpha (IFN-alpha) treatment. Of the 162 chronic hepatitis C patients treated with INF-alpha, 17.9% were GBV-C/HGV RNA-positive and 18.5% anti-E2-positive (total exposure, 35.2%). Neither present nor past GBV-C/HGV infection had impact on the clinical features, HCV virological characteristics and response to IFN-alpha treatment in chronic hepatitis C patients. Among patients with ongoing HCV/GBV-C/HGV coinfection, 20.7% (6/29) in IFN-alpha-treated patients lost GBV-C/HGV RNA concomitant with anti-E2 seropositivity, which was significantly higher than 4.8% (2/42) in patients without INF-alpha treatment (P<0.05). Based on multivariate analyses, the significant factors associated with clearance of GBV-C/HGV viremia combined with anti-E2 seropositivity were baseline anti-E2 seropositivity and IFN-alpha treatment. In summary, GBV-C/HGV did not alter the course of coexistent HCV. IFN-alpha treatment was effective in some patients against GBV-C/HGV and might facilitate anti-E2 seroconversion in chronic hepatitis C patients with GBV-C/HGV viremia.
采用聚合酶链反应检测丙型肝炎病毒G（GBV-C）/庚型肝炎病毒（HGV）RNA，并通过酶联免疫吸附测定检测针对GBV-C/HGV包膜蛋白的抗体（抗-E2），以评估GBV-C/HGV对并存的丙型肝炎病毒（HCV）感染的影响，以及在接受和未接受α干扰素（IFN-α）治疗的慢性丙型肝炎患者中GBV-C/HGV感染的病程。在162例接受INF-α治疗的慢性丙型肝炎患者中，17.9%的患者GBV-C/HGV RNA呈阳性，18.5%的患者抗-E2呈阳性（总感染率为35.2%）。无论是现有的还是既往的GBV-C/HGV感染，均未对慢性丙型肝炎患者的临床特征、HCV病毒学特征及对IFN-α治疗的反应产生影响。在持续HCV/GBV-C/HGV合并感染的患者中，接受IFN-α治疗的患者中有20.7%（6/29）在抗-E2血清学阳性的同时失去了GBV-C/HGV RNA，这一比例显著高于未接受INF-α治疗的患者中的4.8%（2/42）（P<0.05）。基于多因素分析，与GBV-C/HGV病毒血症清除及抗-E2血清学阳性相关的显著因素为基线抗-E2血清学阳性和IFN-α治疗。总之，GBV-C/HGV并未改变并存HCV的病程。IFN-α治疗对部分患者的GBV-C/HGV有效，并可能促进GBV-C/HGV病毒血症慢性丙型肝炎患者的抗-E2血清学转换。
